Labcorp Holdings Inc.

DB:N6B Stock Report

Market Cap: €18.5b

Labcorp Holdings Valuation

Is N6B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of N6B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: N6B (€217) is trading below our estimate of fair value (€707.31)

Significantly Below Fair Value: N6B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for N6B?

Key metric: As N6B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for N6B. This is calculated by dividing N6B's market cap by their current earnings.
What is N6B's PE Ratio?
PE Ratio44.1x
EarningsUS$435.50m
Market CapUS$19.19b

Price to Earnings Ratio vs Peers

How does N6B's PE Ratio compare to its peers?

The above table shows the PE ratio for N6B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.4x
FME Fresenius Medical Care
19.4x19.3%€12.8b
SYAB SYNLAB
27.6x-11.4%€2.5b
SHL Siemens Healthineers
30x14.2%€58.3b
DGX Quest Diagnostics
20.4x11.7%US$17.1b
N6B Labcorp Holdings
44.1x21.9%€19.2b

Price-To-Earnings vs Peers: N6B is expensive based on its Price-To-Earnings Ratio (44.1x) compared to the peer average (24.4x).

Price to Earnings Ratio vs Industry

How does N6B's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
N6B 44.1xIndustry Avg. 18.2xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: N6B is expensive based on its Price-To-Earnings Ratio (44.1x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is N6B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

N6B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.1x
Fair PE Ratio31.6x

Price-To-Earnings vs Fair Ratio: N6B is expensive based on its Price-To-Earnings Ratio (44.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst N6B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€217.00
€250.65
+15.5%
6.6%€279.38€220.26n/a16
Dec ’25€226.00
€248.74
+10.1%
6.4%€279.17€220.10n/a16
Nov ’25€208.00
€240.10
+15.4%
6.5%€269.79€212.70n/a16
Oct ’25€197.50
€227.66
+15.3%
7.9%€254.76€180.67n/a16
Sep ’25€205.00
€224.27
+9.4%
8.7%€248.36€179.31n/a15
Aug ’25€196.00
€222.96
+13.8%
8.8%€254.84€185.33n/a15
Jul ’25€186.50
€221.21
+18.6%
7.3%€243.92€195.51n/a15
Jun ’25€176.50
€220.20
+24.8%
6.7%€241.93€193.91n/a15
May ’25€190.00
€224.43
+18.1%
6.8%€245.44€196.73n/a16
Apr ’25€199.00
€224.15
+12.6%
6.0%€247.16€201.39n/a15
Mar ’25€199.00
€225.85
+13.5%
6.0%€248.83€202.75n/a15
Feb ’25€200.00
€222.43
+11.2%
6.8%€248.91€198.21n/a14
Jan ’25€204.00
€221.93
+8.8%
6.3%€247.32€196.94n/a14
Dec ’24€198.00
€218.40
+10.3%
7.1%€245.78€191.16€226.0014
Nov ’24€188.00
€226.72
+20.6%
7.5%€255.53€198.74€208.0014
Oct ’24€192.00
€230.56
+20.1%
8.6%€267.27€196.94€197.5014
Sep ’24€191.00
€227.72
+19.2%
7.5%€260.35€196.40€205.0014
Aug ’24€194.00
€232.76
+20.0%
9.0%€264.05€195.76€196.0014
Jul ’24€218.00
€246.64
+13.1%
7.2%€265.76€213.52€186.5014
Jun ’24€199.00
€251.63
+26.4%
6.1%€268.42€217.52€176.5014
May ’24€204.00
€252.03
+23.5%
6.7%€273.45€214.20€190.0014
Apr ’24€206.00
€264.97
+28.6%
4.3%€279.60€242.32€199.0013
Mar ’24€225.65
€268.15
+18.8%
4.6%€285.49€244.17€199.0013
Feb ’24€231.30
€256.91
+11.1%
7.6%€289.89€230.08€200.0013
Jan ’24€220.50
€259.85
+17.8%
7.7%€296.32€235.18€204.0013
Dec ’23€229.95
€269.95
+17.4%
7.2%€305.71€242.63€198.0013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 20:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Labcorp Holdings Inc. is covered by 48 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian Kemp DolliverAvondale Partners
Eric ColdwellBaird